Evidence map›Paper›PMID 26114473›Full record

ArticleViruses2015

RNase P Ribozymes Inhibit the Replication of Human Cytomegalovirus by Targeting Essential Viral Capsid Proteins.

Zhu Yang, Michael Reeves, Jun Ye, Phong Trang, Li Zhu, Jingxue Sheng, Yu Wang, Ke Zen, Jianguo Wu, Fenyong Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Viruses, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. MicroRNA750-3p TargetsViruses · 2024
    Article
  2. Review
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Zhu YangInstitute of Virology, School of Life Sciences, Nanjing University, Nanjing 210093, China. sin_angel@foxmail.com.
Michael ReevesSchool of Public Health, University of California, Berkeley, CA 94720, USA. mreeves@berkeley.edu.
Jun YeThe People's Hospital of Taizhou, Taizhou 225300, China. junye1965@hotmail.com.
Phong TrangSchool of Public Health, University of California, Berkeley, CA 94720, USA. phong.trang@berkeley.edu.
Li ZhuThe People's Hospital of Taizhou, Taizhou 225300, China. lizhu1975@hotmail.com.
Jingxue ShengProgram in Comparative Biochemistry, University of California, Berkeley, CA 94720, USA. jxsheng@berkeley.edu.
Yu WangTaizhou Institute of Virology, Taizhou 225300, China. sin_angel@foxmail.com.
Ke ZenInstitute of Virology, School of Life Sciences, Nanjing University, Nanjing 210093, China. kzen@nju.edu.cn.
Jianguo WuState Key Laboratory of Virology and College of Life Sciences, Wuhan University, Wuhan 430072, China. jwu@whu.edu.cn.
Fenyong LiuSchool of Public Health, University of California, Berkeley, CA 94720, USA. liu_fy@berkeley.edu.
University of California, Berkeley · USSingleron Biotechnologies (china) · CNTaizhou People's Hospital · CNNanjing University · CNWuhan University · CN

Funding

RIBOZYMES FOR STUDIES AND TREATMENT OF HCMV INFECTIONSR01AI041927 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIU, FENYONG · 1997 to 2012
$3.7M
Persistent infection of human cytomegalovirus in oral mucosaR01DE025462 · NIDCR · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIU, FENYONG · 2015 to 2019
$2.3M
Human cytomegalovirus chromatin modifications in oral infectionR01DE023935 · NIDCR · UNIVERSITY OF CALIFORNIA BERKELEY · PI LIU, FENYONG · 2013 to 2017
$2.3M
Bacteria Based Agents for Therapy of AIDS Associated InfectionsR01AI091536 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI LU, SANGWEI · 2011 to 2014
$1.3M
NIAID NIH HHS R01 AI041927NIAID NIH HHS R01-AI041927NIAID NIH HHS R01 AI091536NIAID NIH HHS R01-AI091536NIDCR NIH HHS R01 DE023935NIDCR NIH HHS R01-DE023935NIDCR NIH HHS R01 DE025462
6 · The paper itself

Abstract

An engineered RNase P-based ribozyme variant, which was generated using the in vitro selection procedure, was used to target the overlapping mRNA region of two proteins essential for human cytomegalovirus (HCMV) replication: capsid assembly protein (AP) and protease (PR). In vitro studies showed that the generated variant, V718-A, cleaved the target AP mRNA sequence efficiently and its activity was about 60-fold higher than that of wild type ribozyme M1-A. Furthermore, we observed a reduction of 98%-99% in AP/PR expression and an inhibition of 50,000 fold in viral growth in cells with V718-A, while a 75% reduction in AP/PR expression and a 500-fold inhibition in viral growth was found in cells with M1-A. Examination of the antiviral effects of the generated ribozyme on the HCMV replication cycle suggested that viral DNA encapsidation was inhibited and as a consequence, viral capsid assembly was blocked when the expression of AP and PR was inhibited by the ribozyme. Thus, our study indicates that the generated ribozyme variant is highly effective in inhibiting HCMV gene expression and blocking viral replication, and suggests that engineered RNase P ribozyme can be potentially developed as a promising gene-targeting agent for anti-HCMV therapy.

Indexed as

Virus ReplicationCapsid ProteinsCytomegalovirusCytomegalovirus InfectionsGene Expression Regulation, ViralHumansRibonuclease PRNA, CatalyticCapsid ProteinsRibonuclease PRNA, Catalyticcytomegalovirusgene targetinggene therapyribozymeRNase P

Identifiers

PMID26114473
PMCPMC4517104
OpenAlexW1513926712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.